Please share your phone number so we can contact you to learn about your health complaint.
Lutetium-177 therapy (Lu-177 therapy) is one of the most advanced targeted radionuclide therapies developed for cancer treatment. It has shown remarkable results in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain neuroendocrine tumors (NETs).
The therapy uses a radioactive isotope, Lutetium-177, which is attached to molecules that specifically target receptors on cancer cells. Once bound, Lu-177 delivers beta radiation directly to the tumor, destroying cancer cells while minimizing damage to surrounding healthy tissue.
Advanced prostate cancer (mCRPC) after hormonal and chemotherapy options fail.
Neuroendocrine tumors (NETs), especially those expressing somatostatin receptors.
Currently under research for other solid tumors.
Lutetium-177 therapy is given intravenously in specialized nuclear medicine centers.
Treatment usually consists of multiple cycles every 6–8 weeks, depending on patient response.
Prolonged survival in advanced cancer patients.
Relief of cancer-related symptoms such as pain.
Tumor shrinkage or stabilization of disease progression.
Fatigue and weakness.
Nausea and loss of appetite.
Low white blood cells or platelet counts.
Dry mouth (in NET patients).
Rarely, kidney or bone marrow toxicity.
Lutetium-177 therapy in Egypt is available in a few specialized centers and remains an expensive treatment due to its advanced technology and global demand.
Lutetium-177 therapy offers new hope for patients with advanced prostate cancer and neuroendocrine tumors, especially when conventional therapies are no longer effective.
The medical information provided about Lutetium-177 therapy is for educational purposes only and does not replace professional medical advice. Always consult a qualified physician before starting or changing any treatment.
If you want to learn more about Lutetium-177 therapy in Egypt or book a consultation with an oncology specialist, contact Macrocare today for:
Assistance with arranging treatment sessions.
Expert consultation with oncologists and nuclear medicine specialists.
Comprehensive follow-up and patient care.